In which patients is lenacapavir indicated, i.e., adults ≥ 18 years with HIV‑1 infection who have limited treatment options due to multi‑class resistance and require a long‑acting injectable regimen?

Lenacapavir Target Population

Lenacapavir is indicated for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations 1.

Specific Patient Criteria

The FDA-approved indication is highly specific and requires ALL of the following:

• Adults (≥18 years of age) with HIV-1 infection
• Heavily treatment-experienced (not for first-line or early-line therapy)
• Multidrug-resistant HIV-1 documented by genotypic testing
• Current regimen failing due to one or more of:
  • Resistance (most common indication)
  • Intolerance to current medications
  • Safety considerations with current regimen

1

Clinical Context from Real-World Use

While the FDA label is restrictive, real-world data reveals lenacapavir is being used more broadly in clinical practice. In the OPERA cohort, 56% of patients simplified their regimen at lenacapavir initiation, and only 26% had documented multidrug-resistant HIV at baseline 2. This suggests clinicians are using lenacapavir for factors beyond just virologic failure—including safety, tolerability, and regimen simplification 2.

However, for regulatory approval and reimbursement purposes, the strict FDA indication must be met: heavily treatment-experienced adults with multidrug resistance and failing current therapy 1.

Key Clinical Outcomes

In the pivotal CAPELLA trial of this exact population:

• 81-83% achieved viral suppression (<50 copies/mL) at week 26 3
• 62% maintained suppression at week 104 by FDA snapshot (82% when excluding discontinuations) 4
• Mean CD4 count increased by 122 cells/µL at week 104 4
• Well-tolerated with no Grade 4 or serious treatment-related adverse events 4

Important Caveats

Lenacapavir must be used in combination with other antiretrovirals—it is never used as monotherapy. Ideally, combine with at least 1-2 additional fully active agents based on resistance testing 5, 3.

This is NOT for PrEP or treatment-naive patients under current FDA approval, despite ongoing trials in those populations 6.